Small Pharma’s psychedelic drug helps reduce depression symptoms in mid-stage study

Brain nerve electric signal simulation


Small Pharma’s (OTCQB:DMTTF) psychedelic drug SPL026, with supportive therapy, met the main goal of showing reduction in depression symptoms in phase 2a trial.

The two-staged Phase 2a study included evaluated a single dose of SPL026 (intravenous N,N-Dimethyltryptamine (DMT)) with supportive therapy (N=17) versus placebo

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!